免疫原性细胞死亡
肿瘤微环境
癌症研究
免疫疗法
医学
免疫检查点
癌症
CD8型
癌症免疫疗法
前药
免疫系统
吉西他滨
联合疗法
PD-L1
药理学
免疫学
内科学
作者
Xiaowei Shi,Liwei Shu,Min-Wen Wang,Jie Yao,Qigu Yao,Suchen Bian,Xiaona Chen,Jianqin Wan,Fu Zhang,Shusen Zheng,Hangxiang Wang
出处
期刊:Advanced Science
[Wiley]
日期:2023-04-05
卷期号:10 (15): e2204890-e2204890
被引量:35
标识
DOI:10.1002/advs.202204890
摘要
Abstract Immune checkpoint blockade (ICB) therapies have had a tremendous impact on cancer therapy. However, most patients harbor a poorly immunogenic tumor microenvironment (TME), presenting overwhelming de novo refractoriness to ICB inhibitors. To address these challenges, combinatorial regimens that employ chemotherapies and immunostimulatory agents are urgently needed. Here, a combination chemoimmunotherapeutic nanosystem consisting of a polymeric monoconjugated gemcitabine (GEM) prodrug nanoparticle decorated with an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody (αPD‐L1) on the surface and a stimulator of interferon genes (STING) agonist encapsulated inside is developed. Treatment with GEM nanoparticles upregulates PD‐L1 expression in ICB‐refractory tumors, resulting in augmented intratumor drug delivery in vivo and synergistic antitumor efficacy via activation of intratumor CD8+ T cell responses. Integration of a STING agonist into the αPD‐L1‐decorated GEM nanoparticles further improves response rates by transforming low‐immunogenic tumors into inflamed tumors. Systemically administered triple‐combination nanovesicles induce robust antitumor immunity, resulting in durable regression of established large tumors and a reduction in the metastatic burden, coincident with immunological memory against tumor rechallenge in multiple murine tumor models. These findings provide a design rationale for synchronizing STING agonists, PD‐L1 antibodies, and chemotherapeutic prodrugs to generate a chemoimmunotherapeutic effect in treating ICB‐nonresponsive tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI